Gilead Sciences (LTS:0QYQ) Short-Term Debt : $0 Mil (As of Mar. 2025)

View and export this data going back to 2018. Start your Free Trial

What is Gilead Sciences Short-Term Debt?

Gilead Sciences's Short-Term Debt for the quarter that ended in Mar. 2025 was $0 Mil.

Gilead Sciences's quarterly Short-Term Debt increased from Sep. 2024 ($1,812 Mil) to Dec. 2024 ($1,815 Mil) but then declined from Dec. 2024 ($1,815 Mil) to Mar. 2025 ($0 Mil).

Gilead Sciences's annual Short-Term Debt declined from Dec. 2022 ($2,273 Mil) to Dec. 2023 ($1,798 Mil) but then increased from Dec. 2023 ($1,798 Mil) to Dec. 2024 ($1,815 Mil).

Gilead Sciences Short-Term Debt Historical Data

The historical data trend for Gilead Sciences's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gilead Sciences Short-Term Debt Chart

Gilead Sciences Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Short-Term Debt

Get a 7-Day Free Trial

2,757.00

1,516.00

2,273.00

1,798.00

1,815.00

Gilead Sciences Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Short-Term Debt	Get a 7-Day Free Trial															3,667.00	1,810.00	1,812.00	1,815.00	-

Gilead Sciences Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Gilead Sciences Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Gilead Sciences's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Gilead Sciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Gilead Sciences Inc (LTS:0QYQ) » Definitions » Short-Term Debt

Comparable Companies

Traded in Other Exchanges

GILD:USA GILD:Mexico 1GILD:Italy GISd:UK GIS:Germany GILD34:Brazil GILD:Austria GILD:Argentina

Address

333 Lakeside Drive, Foster City, CA, USA, 94404

Website

https://www.gilead.com

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).

Gilead Sciences Headlines

No Headlines